GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Skye Bioscience Inc (NAS:SKYE) » Definitions » Cyclically Adjusted PB Ratio

Skye Bioscience (Skye Bioscience) Cyclically Adjusted PB Ratio : (As of May. 21, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Skye Bioscience Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Skye Bioscience Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Skye Bioscience's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Skye Bioscience Cyclically Adjusted PB Ratio Chart

Skye Bioscience Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Skye Bioscience Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Skye Bioscience's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Skye Bioscience's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Skye Bioscience's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Skye Bioscience's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Skye Bioscience's Cyclically Adjusted PB Ratio falls into.



Skye Bioscience Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Skye Bioscience's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Skye Bioscience's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=2.811/131.7762*131.7762
=2.811

Current CPI (Mar. 2024) = 131.7762.

Skye Bioscience Quarterly Data

Book Value per Share CPI Adj_Book
201404 2.135 100.023 2.813
201407 2.368 100.520 3.104
201412 -7.094 99.070 -9.436
201503 -5.195 99.621 -6.872
201506 -13.234 100.684 -17.321
201509 -8.215 100.392 -10.783
201512 -11.205 99.792 -14.796
201603 -29.755 100.470 -39.026
201606 -20.276 101.688 -26.275
201609 -29.868 101.861 -38.640
201612 -33.786 101.863 -43.708
201703 -26.355 102.862 -33.763
201706 -24.122 103.349 -30.757
201709 -26.321 104.136 -33.307
201712 -26.537 104.011 -33.621
201803 -10.864 105.290 -13.597
201806 -15.533 106.317 -19.253
201809 -19.025 106.507 -23.539
201812 -29.054 105.998 -36.120
201903 -52.021 107.251 -63.917
201906 -21.703 108.070 -26.464
201909 -30.579 108.329 -37.198
201912 0.749 108.420 0.910
202003 -2.324 108.902 -2.812
202006 -4.222 108.767 -5.115
202009 1.852 109.815 2.222
202012 0.391 109.897 0.469
202103 1.686 111.754 1.988
202106 1.433 114.631 1.647
202109 4.340 115.734 4.942
202112 3.079 117.630 3.449
202203 1.499 121.301 1.628
202206 -0.152 125.017 -0.160
202209 -1.656 125.227 -1.743
202212 -0.823 125.222 -0.866
202303 -1.230 127.348 -1.273
202306 -2.004 128.729 -2.051
202309 0.137 129.860 0.139
202312 -0.173 129.419 -0.176
202403 2.811 131.776 2.811

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Skye Bioscience  (NAS:SKYE) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Skye Bioscience Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Skye Bioscience's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Skye Bioscience (Skye Bioscience) Business Description

Traded in Other Exchanges
N/A
Address
11250 El Camino Real, Suite 100, San Diego, CA, USA, 92130
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. It researches and develops and plans to commercialize cannabinoid derivatives through its own directed research efforts and through several license agreements with the University of Mississippi. The company's lead compound, SBI-100, is initially being developed to treat ocular disease.
Executives
Punit Dhillon director 5820 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
John D Diekman 10 percent owner C/O 5 AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Partners Vii, Llc 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Paul A. Grayson director 10578 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
5am Ventures Vii, L.p. 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Kush Parmar 10 percent owner C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Partners Ii, Llc 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Co-investors Ii Lp 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Versant Ventures Iii, Llc 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Scott M Rocklage 10 percent owner C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Andrew J. Schwab director, 10 percent owner C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Versant Side Fund Iii, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
5am Ventures Ii Lp 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Versant Venture Capital Iii, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Deborah H. Charych director 1001 17TH ST, SAN FRANCISCO CA 94107

Skye Bioscience (Skye Bioscience) Headlines

From GuruFocus